Wadsworth Center, New York State Department of Health, Albany, NY 12201-0509, USA.
J Chromatogr A. 2009 Nov 20;1216(47):8289-95. doi: 10.1016/j.chroma.2009.05.036. Epub 2009 May 21.
The isolation and analysis of circulating tumor cells (CTCs) from blood are the subject of intense research. Although tests to detect metastasis on a molecular level are available, progress has been hampered by a lack of tumor-specific markers and predictable DNA abnormalities. The main challenge in this endeavor is the small number of available cells of interest, 1-2 per mL in whole blood. We have designed a micromachined device to fractionate whole blood using physical means to enrich for and/or isolate rare cells from peripheral circulation. It has arrays of four successively narrower channels, each consisting of a two-dimensional array of columns. Current devices have channels ranging in width from 20 to 5 microm, and in depth from 20 to 5 microm. Several optimizations resulting in the fabrication of a total of 10 derivative devices have been carried out; only two types are used in this study. Both have increasingly narrower gap widths between the columns along the flow axis with 20, 15, 10, and 5 microm spacing all on one device. The first 20 microm wide segment disperses the cell suspension and creates an evenly distributed flow over the entire device, whereas the others were designed to retain increasingly smaller cells. The channel depth is constant across the entire device, the first type was 10 microm deep and the second type is 20 microm deep. When cells from each of eight tumor cell lines were loaded into the device, all cancerous cells were isolated. In mixing experiments using human whole blood, we were able to fractionate cancer cells without interference from the blood cells. Additionally, either intact cells, or DNA, could be extracted for molecular analysis. The ultimate goal of this work is to characterize the cells on the molecular level to provide non-invasive methods to monitor patients, stage disease, and assess treatment efficacy. Furthermore, this work will use gene expression profiles to gain insights into metastasis.
从血液中分离和分析循环肿瘤细胞(CTC)是目前研究的热点。尽管已经有检测分子水平转移的方法,但由于缺乏肿瘤特异性标志物和可预测的 DNA 异常,研究进展一直受到阻碍。这项工作的主要挑战是,感兴趣的细胞数量很少,每毫升全血中只有 1-2 个细胞。我们设计了一种微加工设备,通过物理手段对全血进行分离,以富集和/或分离外周循环中的稀有细胞。它有四组依次变窄的通道,每个通道都由二维的列阵组成。目前的设备的通道宽度从 20 到 5 微米不等,深度从 20 到 5 微米不等。已经进行了几项优化,总共制造了 10 个衍生设备;本研究仅使用两种类型。这两种类型的设备都沿着流动轴在列之间具有越来越窄的间隙宽度,其中一种设备的间距为 20、15、10 和 5 微米,另一种设备的间距为 20 微米。前 20 微米宽的部分分散细胞悬浮液,并在整个设备上形成均匀分布的流动,而其他部分则用于保留越来越小的细胞。通道深度在整个设备中保持不变,第一种类型的深度为 10 微米,第二种类型的深度为 20 微米。当将来自八种肿瘤细胞系的细胞加载到设备中时,所有癌细胞都被分离出来。在使用人全血进行混合实验时,我们能够在不干扰血细胞的情况下对癌细胞进行分离。此外,还可以提取完整细胞或 DNA 进行分子分析。这项工作的最终目标是对细胞进行分子水平的表征,提供非侵入性的方法来监测患者、分期疾病和评估治疗效果。此外,这项工作将使用基因表达谱来深入了解转移。